12/7 Early treatment study
et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (preprint 12/7) (Peer Reviewed)
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
Tiny RCT for early treatment of mild COVID-19 in low risk patients, with 12 400mcg/kg single dose ivermectin patients and 12 control patients, showing significantly faster viral load reduction and symptom improvement with ivermectin.Average median viral load for gene E and gene N mid-viral recovery at day 7:Ivermectin: 1637
control: 30175Probability of symptoms at day 28, adjusted for the time since onset and day of followup:Ivermectin: = 0.26 [0.10-0.42]
control: 0.55 [0.33-0.77](details are in the supplementary appendix)
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
control: 30175Probability of symptoms at day 28, adjusted for the time since onset and day of followup:Ivermectin: = 0.26 [0.10-0.42]
control: 0.55 [0.33-0.77](details are in the supplementary appendix)
Chaccour et al., 12/7/2020, Double Blind Randomized Controlled Trial, Spain, Europe, peer-reviewed, 23 authors, dosage 400μg/kg single dose.
symptom probability, 52.9% lower, RR 0.47, p < 0.05, treatment 12, control 12, relative probability of symptoms at day 28, mixed effects logistic regression, data in supplementary appendix.
viral load, 94.6% lower, relative load 0.05, treatment 12, control 12, day 7 mid-recovery, data in supplementary appendix.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary;
multiple approaches are required to cover all people and all existing and
future variants. We do not provide medical advice. Before taking any
medication, consult a qualified physician who can provide personalized advice
and details of risks and benefits based on your medical history and situation.
Treatment protocols for physicians are available from the FLCCC.